TAK
Oof, that’s a big check
Takeda says a jury in the U.S. District Court for the District of Massachusetts ruled against it in the AMITIZA, aka lubiprostone, antitrust litigation. The verdict: $884.9 million. That is not exactly pocket change — even for a global pharma giant.
Why investors should care
This isn’t just a legal footnote tucked away in a filing drawer. A verdict that large can hit reported results, force a revision to FY25 expectations, and add a nice little cloud over the company’s near-term financials. In other words: the kind of event that makes accountants reach for extra coffee.
The bigger takeaway
For Takeda shareholders, the main question now is whether this becomes a one-off hit or the start of a longer legal overhang. Either way, a jury award this large can ripple through earnings, guidance, and how investors think about risk in the stock.
Big picture: pharma is supposed to be about blockbuster drugs, not blockbuster verdicts — but here we are.